

Dear Colleague

**Public Health Service: Emergency Hormonal
Contraception
Patient Group Directions**

Summary

1. This Circular advises of an amended Patient Group Directions template in respect of the Emergency Hormonal Contraception service available through community pharmacies.

Background

2. NHS Circular [PCA \(P\) \(2008\) 17](#) attached revised Directions for Additional Pharmaceutical Services, including the introduction of Emergency Hormonal Contraception (EHC).

3. This Circular advises of a new Patient Group Directions (PGD) template for the administration by community pharmacists of Levonorgestrel 1500 micrograms for the Public Health Service (PHS) EHC service.

Details

4. The new PGD template is attached at Annex A to this Circular, and has been developed by the Scottish Primary Care Pharmacy Group.

5. Community Pharmacy Scotland has been consulted on the content of this Circular.

6 February 2015

Addresses

For action

Chief Executives, NHS Boards

For information

Chief Executive
NHS NSS

Enquiries to:

Brian O'Donnell
Pharmacy & Medicines Division
1st Floor East Rear
St Andrew's House
EDINBURGH
EH1 3DG
Tel: 0131 244 2524
email:
Brian.O'Donnell@scotland.gsi.gov.uk

www.scotland.gov.uk

Action

6. **NHS Boards are asked to ensure that they have an amended and updated PGD in force in accordance with the attached template, and to ensure that it continues to be maintained in the absence of any further advice.**

Yours sincerely



Bill Scott

Chief Pharmaceutical Officer and
Deputy Director, Pharmacy & Medicines Division



Patient Group Direction For the administration of Levonorgestrel 1500micrograms by Pharmacists, for Emergency Hormonal Contraception

This specimen Patient Group Direction template has been developed by the Scottish Primary Care Pharmacy Group to assist NHS boards

NHS boards should amend/adapt this Patient Group Direction template and must ensure that the Patient Group Direction is considered and approved in line with local clinical governance arrangements for Patient Group Directions

1. Authorisation

This specimen Patient Group Direction (PGD) template has been produced by the Primary Care Pharmacy Group to assist NHS boards. NHS boards should ensure that the final PGD is considered and approved in line with local clinical governance arrangements for PGDs.

The qualified health professionals who may administer levonorgestrel 1500micrograms under this PGD can only do so as named individuals. **It is the responsibility of each professional to practice within the bounds of their own competence and in accordance with their own Code of Professional Conduct and to ensure familiarity with the marketing authorisation holder's summary of product characteristics (SmPC) for all medicines administered in accordance with this PGD.**

NHS board governance arrangements will indicate how records of staff authorised to operate this PGD will be maintained. Under PGD legislation there can be no delegation.

Administration of the medicine has to be by the same practitioner who has assessed the patient under the PGD.

**This PGD has been produced for
NHS (*insert details*) by**

Doctor _____ Signature

Pharmacist _____ Signature

Nurse _____ Signature

**Approved on behalf of NHS (*insert
details*) by**

Medical Director _____ Signature

Director of Pharmacy/Senior
Pharmacist _____ Signature

Clinical Governance Lead _____ Signature

Date Approved _____

Effective from _____ Review
Date _____

2. Management of the National Patient Group Direction (PGD)

The original signed copy should be held by the NHS Board.

This PGD must be read, agreed to, signed and a copy retained by all pharmacists involved in its use. A copy of the signature sheet should be sent to the NHS Board.

3. Application

This PGD covers the supply of levonorgestrel 1500micrograms tablet for use as emergency hormonal contraception by female patients who are aged 13 years or over, provided none of the exclusion criteria listed below apply.

4. Clinical Situation

<p>Indication</p>	<p>Patient presenting in person at the community pharmacy requesting emergency contraception for their own use within 72 hours of unprotected sexual intercourse (UPI).</p>
<p>Inclusion Criteria</p>	<p>Patient is aged 13 years or over.</p> <p>Unprotected sexual intercourse/contraception failure within the last 72 hours.</p> <p>Unprotected sexual intercourse/contraception failure within the last 72 hours where patient has vomited within 2 hours of taking a dose of levonorgestrel for emergency hormonal contraception.</p> <p>Patient gives their consent to providing the relevant clinical information to the pharmacist after pharmacist has assessed their capacity to consent (see under Staff).</p>
<p>Exclusion Criteria</p>	<p>Patient is aged 12 years or under. The Child Protection Team must be contacted for children of 12 years and under, who present having had sexual intercourse.</p> <p>Patient who the pharmacist has assessed as not being competent to consent.</p> <p>Unexplained vaginal bleeding.</p> <p>Patient has had unprotected sex more than 72 hours ago.</p> <p>Levonorgestrel should not be given to pregnant women.</p> <p>Previous unprotected sexual intercourse in current menstrual cycle.</p> <p>Patient used levonorgestrel for emergency hormonal contraception in current menstrual cycle. (If patient has vomited within 2 hours of taking a dose of levonorgestrel, dose can be repeated. Refer to Inclusion Criteria.)</p> <p>Severe hepatic dysfunction.</p> <p>History of salpingitis or ectopic pregnancy.</p> <p>Severe malabsorption syndromes e.g. severe diarrhoea, Crohns disease.</p> <p>Porphyria.</p> <p>Hypersensitivity to levonorgestrel or any of the tablet ingredients/</p>

	<p>excipients (potato starch, maize starch, colloidal silica anhydrous, magnesium stearate, talc, lactose monohydrate).</p> <p>Patients who have delivered a baby within last 3 weeks (EHC not required in these circumstances).</p> <p>Patient does not agree to share relevant clinical information or there is no valid consent.</p> <p>Patients with hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption as contains 142.5 mg lactose.</p>
<p>Cautions /Need for further advice/ Circumstances when further advice should be sought from a doctor</p>	<p>The available data are limited and not robust enough to support with certainty the conclusion of decreased contraceptive effect with increased bodyweight/BMI.</p> <p>In order to maximise the likelihood that Levonorgestrel will work, it is important that it is taken as soon as possible after unprotected intercourse.</p>
<p>Action if Excluded</p>	<p>All excluded patients should be referred to Sexual Health Service or GP practice. Direct referral process contained within the Unscheduled Care Folder should be used during out of hours period.</p> <p>If unprotected sex was within the last 5 days (120 hours) the patient may be suitable for IUD (intrauterine device) insertion or use of Ulipristal. Assessment or referral should be made in a suitable timeframe to allow this to happen.</p>
<p>Action if Patient Declines</p>	<p>Patient should be advised of the risks of the consequences of not receiving treatment.</p> <p>Record outcome in Patient Medication Record if appropriate and refer the patient to their general practitioner</p> <p>Direct Referral process contained within the Unscheduled Care Folder should be used during out of hours period.</p>
<p>Consent</p>	<p>Prior to the supply of levonorgestrel, consent must be obtained, preferably written, from the patient. Where a patient does not have capacity to consent then this may be provided by a parent, guardian or person with parental responsibility.</p>

	<p>Written and verbal information should be available in a form that can be easily understood by the person who will be giving the consent. Where English is not easily understood, translations and properly recognised interpreters should be used.</p> <p>Individuals (patient, parent, guardian or person with parental responsibility) should also be informed about how data on the supply will be stored, who will be able to access that information and how that data may be used.</p>
<p>Consent for under 16s</p>	<p>A patient under 16 years of age may give consent for the supply of EHC, provided she understands fully the benefits and risks involved. The patient should be encouraged to involve a parent/guardian, if possible, in this decision.</p> <p>Where there is no parental involvement and the patient indicates that she wishes to accept the supply, supply should proceed, if the pharmacist deems the patient to have the legal capacity to consent.</p> <p>The Age of Legal Capacity (S) Act 1991, s2(4) states that 'a person under the age of 16 years shall have legal capacity to consent on her own behalf to any surgical, medical or dental procedure or treatment where, in the opinion of a qualified medical practitioner attending her, she is capable of understanding the nature and possible consequences of the procedure or treatment.'</p> <p>Legal advice from the NHS in Scotland states that if a healthcare professional has been trained and professionally authorised to undertake a clinical procedure which is normally that of a medical practitioner, then that health care professional can be considered to have the necessary power to assess the capacity of a child under the 1991 Act, for that procedure or treatment.</p>

5. Description of Treatment

Name of Medicine	Levonorgestrel
Form/Strength	Tablet 1500 microgram (mcg)
Dosage	<p>Female patients of 13 years and over – Take 1500micrograms as a single oral dose as soon as possible after coitus (preferably within 12 hours but no later than 72 hours after the event).</p> <p>If the patient is using an enzyme-inducing medication or has stopped taking such medication within the last 28 days (see interacting medications), then TWO tablets of levonorgestrel 1500micrograms should be taken as the single dose (total dose 3000micrograms levonorgestrel). This is an unlicensed indication for levonorgestrel not included in the Summary of Product Characteristics (SPC) but is a recommendation of the Faculty of Sexual and Reproductive Healthcare Clinical Guidance on Emergency Contraception.</p> <p>Patients taking enzyme inhibiting medication may experience adverse effects and may require additional monitoring (see interacting medications)</p> <p>If vomiting occurs within 3 hours of taking the original dose, another dose should be taken immediately.</p>
Total Dose	1500micrograms (one tablet) as a single dose, or 3000micrograms (two tablets) as a single dose if patient also taking enzyme-inducing medication or has stopped taking such within last 28 days.
Duration of Treatment	Single oral dose, preferably within 12 hours but no later than 72 hours. If vomiting occurs within 2 hours of taking the original dose, another dose should be taken immediately.
Advice to Patient (verbal)	<p>Advise women using liver enzyme-inducing drugs that an IUD is the preferred option.</p> <p>Discuss the mode of action, failure rate and possible effects on the foetus of levonorgestrel - See relevant SPC. There is no clinical data on effect on foetus by levonorgestrel but it should be avoided. If pregnancy is a possibility this should be excluded before supply is</p>

made.

For patients who have missed their oral contraceptive pill, give advice based on the EHC e learning module developed by NES Pharmacy which can be found at <https://www.portal.scot.nhs.uk/> or the Faculty of Sexual and Reproductive Health Statement on missed pills
<http://www.fsrh.org/pdfs/CEUStatementMissedPills.pdf>

If the patient is taking the oral contraceptive pill or using the contraceptive patch and emergency hormonal contraception is required, advise the patient to use a barrier method in addition to her usual method until she has taken the pill or applied the patch correctly for 7 consecutive days. (If taking Qlaira® - 9 days)

If the patient is not using an oral contraceptive pill, a barrier method of contraception should be used until appropriate contraceptive advice from Sexual Health Service or GP is given.

Highlight that the patient's next period may be early or late.

Advise the patient that levonorgestrel may cause nausea and/or vomiting. If vomiting, or serious diarrhoea, occurs within two hours of taking the medication further advice should be sought immediately from the pharmacist, or other appropriate agency.

Advise the patient that Levonorgestrel is an occasional method of contraception and must not be used as a replacement for a regular contraceptive method. Provide local information about how to access a local contraception service and contraceptive advice

Advise the patient that they should consider being tested for a sexually transmitted infection and provide local information about where they can obtain that service.

If the patient has not had their period within 5 days of their expected date of menstruation, abnormal bleeding occurs or pregnancy is suspected, they should be advised to attend the Sexual Health Service, GP or pharmacy (if pregnancy testing is provided) with a urine sample to confirm or exclude pregnancy.

	<p>If patient is breast-feeding, advise levonorgestrel is not thought to be harmful <i>but potential exposure of their baby can be reduced if patient takes the dose immediately after feeding.</i></p> <p>Requirements of oral anti-diabetics and insulin can change as a result of taking levonorgestrel therefore the patient with diabetes should be advised to monitor blood glucose levels closely.</p> <p>The available data are limited and not robust enough to support with certainty the conclusion of decreased contraceptive effect with increased bodyweight/BMI</p>
Patient Information (written)	<ol style="list-style-type: none"> 1. Patient Information Leaflet provided with medication. 2. Written information about locally available contraception services and methods of contraception. 3. Written information about locally available services providing sexual health advice.
Documentation	<p>The pharmacist must ensure maintenance of records for each supply (For example see appendix 1) and may be required to share information with appropriate parties in line with confidentiality protocols.</p>
Follow-up	<p>None required.</p>
Storage requirements	<p>Store in original container below 25°C</p>
Additional Information	<p><i>Reduced efficacy of Levonorgestrel</i></p> <p>The metabolism of levonorgestrel is enhanced by concomitant use of liver enzyme inducers or use within the last 28 days, and these medications can reduce the efficacy of levonorgestrel. A full list is available in Appendix 1 of the relevant section of the British National Formulary, or in the SPC for the product being used. These include:</p> <p>Anticonvulsants: Barbiturates (including Primidone), Phenytoin, Carbamazepine, Topiramate. Anti-Fungal: Griseofulvin</p>

	<p>Herbal Medicines containing <i>Hypericum perforatum</i> (St. John's wort).</p> <p>Rifamycins: Rifampicin, Rifabutin</p> <p>Endothelin receptor antagonist: Bosentan</p> <p><i>Effect of Levonorgestrel on other medication</i></p> <p>Immunosuppressants: metabolism of ciclosporin reduced (increased plasma concentration). Increased risk of toxicity. Additional monitoring may be required.</p> <p>Caution is advised when prescribing for patients using the anticoagulant drugs, phenindione and warfarin. Anticoagulant effects may be altered following use. Additional monitoring may be required. Patients should be advised about potential drug interactions and attention should be paid to their anticoagulation monitoring.</p>
<p>Warnings including possible adverse reactions</p>	<p>Menstrual irregularities, nausea, low abdominal pain, fatigue, headache, dizziness, breast tenderness, vomiting.</p> <p>All adverse reactions (actual and suspected) will be reported to the appropriate medical practitioner and recorded in the appropriate place (e.g. the Minor Injury Record Sheet or the Allergies and Adverse Reactions section of the Patient Record). Where appropriate a Yellow Card Report will be forwarded to the Committee on Safety of Medicines. A supply of these forms can be found at the rear of the British National Formulary. Online reporting is available at http://yellowcard.mhra.gov.uk/</p>
<p>Patient Charges</p>	<p>None. Current NHS exemption is applicable.</p>
<p>References</p>	<ol style="list-style-type: none"> 1. British National Formulary – Current edition 2. Faculty of Sexual and Reproductive Health Guidance CEU (August 2011, updated January 2012) “Emergency contraception”. 3. Levonelle® 1500 microgram tablet SPC – Updated 15.2.2012 4. Upostelle 1500microgram tablet SPC – updated 15.3.2013 5. NES – Emergency Hormonal Contraception e learning module

which can be found at <https://www.portal.scot.nhs.uk/>

Characteristics of staff authorised under the PGD

Professional qualifications	A person whose name is currently maintained on the register of pharmacists held by the General Pharmaceutical Council (GPhC) The pharmacist must maintain their own level of competence and knowledge in this area to provide the service.
Specialist competencies or qualifications	The practitioner should be competent to assess the person's capacity to understand the nature and purpose of the treatment in order to give or refuse consent.
Continuing education and training	The practitioner must be familiar with the SmPC for all medicines administered in accordance with this PGD. It is the responsibility of the individual to keep up to date with all aspects of practice in this area.

Audit Trail

Record/Audit Trail	<p>The approved practitioner must ensure maintenance of records for each supply and may be required to share information with appropriate parties in line with confidentiality protocols. The information relating to the supply of medication of each individual must include as a minimum:</p> <ul style="list-style-type: none">• Patient's name and date of birth,• Dose,• Brand, batch number and expiry date of medicine,• Date given and by whom. <p>All records must be clear and legible and, ideally, in an easily retrievable format.</p> <p>Depending on the clinical setting where the supply of medication is undertaken, the information should be recorded manually or electronically, in one (or more) of the following systems, as appropriate:</p> <ul style="list-style-type: none">• GP practice computer,• Individuals GP records.
--------------------	--

Appendix 1

EXAMPLE EMERGENCY HORMONAL CONTRACEPTION PROFORMA

DATE:		CLIENT NAME:	
CHI:		AGE:	

Pharmacy Stamp

If 13, 14,15 YEARS OLD	
EXPLAIN CONFIDENTIALITY AND LIMITS	
Who is with her?	Who knows where she is?
Hold old is partner?	Lives with family / friends / in care / homeless
Attends school Y / N	Concerns drugs / alcohol? Y / N
Concerns re assault / abuse? Y / N	
COMPETENT TO CONSENT	Yes
	Not competent / under 13 yrs old / child protection issues
	Inform Police

Last Menstrual Period:	NORMAL?	Y/N		CYCLE	(DAYS)	REGULAR?	Y/N	
1. PREGNANCY TEST	NOT DONE			NEGATIVE		POSITIVE		
(Do test if period late or LMP unsure or LMP unusual)								
CIRCUMSTANCES	2. 3. SI	UP	CONTRACEPTIVE FAILURE	OTHER:				

WHEN WAS THE FIRST UPSI SINCE THE START OF HER LAST PERIOD OR SINCE HORMONAL METHOD FAILURE?

DATE		TIME	
HOURS SINCE DAY IN CYCLE OF 1ST UPSI			72 hours since 1st UPSI Consider Ulipristal acetate refer to national PGD
	NO	YES	
ANY EHC ALREADY THIS CYCLE?			If already used EHC this cycle – Refer
SEXUAL ASSAULT?			If assault refer to local guidelines
PREVIOUS VOMIT WITH EHC?			
MEDICAL HISTORY:	NO	YES	
KNOWN ALLERGY TO LEVONORGESTREL			If YES Consider Ulipristal acetate or Refer
SEVERE HEPATIC DYSFUNCTION			If YES Refer
SEVERE ABSORPTION DIFFICULTIES			If YES Refer
PORPHYRIA			If YES Refer

SEVERE MALABSORPTION SYNDROME			If YES Refer
UNEXPLAINED VAGINAL BLEEDING			If YES Refer
ON INTERACTING MEDICATION			If YES Consider Ulipristal acetate or refer
ENZYME INDUCING MEDICATION			If YES, refer for IUD or double dose EHC

(Refer to current BNF)

CONCEPTION RISK for a 25 yr old after 1 episode of UPSI	
Days 8-17	20-30% risk of pregnancy
Days 1-7 and >17	2-3% risk of pregnancy
POSTCOITAL CONTRACEPTION OPTIONS	
Levonogestrel within 72 hours	
Levonogestrel 72 – 120 hours (off licence) - Refer	
Mifepristone 72 – 120 hours (off licence) - Refer	
Ulipristal up to 120 hours - Consider use and refer to national PGD	
Copper IUD up to 120 hrs after UPSI / or 120hrs after predicted ovulation - Refer	
BOTH ORAL AND IUD EMERGENCY CONTRACEPTION DISCUSSED	

PLANNED TREATMENT

Levonorgestrel 1500 mcg as single dose (PGD supply)		Too late for tablets but declines IUD or Ulipristal	
Levonorgestrel 3 mg single dose (enzyme inducers) (PGD supply – off licence)		Too late for any EHC	
		No EHC needed at all	
Referred for IUD: Referred for STI testing Referred for Contraceptive Advice:		Details:	

CURRENT CONTRACEPTION

Patch COC POP Injection Implant IUD/S

Other _____

Continue pills / patch + condoms too for 7 days
Start pills / patch first day of next period

ADVICE CHECKLIST

How to take tablets		Failure rate	
Action if vomits within 2 hours		Pregnancy test in 3 weeks unless normal period	
Next period may be early/late		If levonorgestrel EHC fails not harmful to pregnancy	
Return if further UPSI		Written information on access to regular contraception	
May be light bleeding next few days, don't count as period			

SEXUALLY TRANSMITTED INFECTION

STI risk discussed		14 day window period for Chlamydia, and Gonococcal swabs		3 month window period for Syphilis, Hepatitis B, C, HIV	
--------------------	--	--	--	---	--

Provide written information on STI testing services

LEVONORGESTREL SUPPLY

BATCH NUMBER _____

EXPIRY _____

SIGNATURE OF PHARMACIST _____

PRINT NAME _____

_____ **DATE**